Skip to content

Ayurveda clinical trial on mildly symptomatic COVID- 19 patientsâ??

A Prospective, Open Label, Three Arm, Controlled Study to Assess The Immune-Boosting Activity of Jeevaneeyam Tablets Plus Ojovardhini Capsule (Test Formulation A), Amrutha Sanjeevini Tablets plus Ojovardhini capsule (Test Formulation B) in mildly symptomatic COVID- 19 patients

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/02/031353
Enrollment
60
Registered
2021-02-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Jeevaneeyam Tablets Plus Ojovardhini Capsule (Test Formulation A): Dosage form: Tablet and capsule Frequency : 14 days Twice a day morning and evening after meal Intervention2: Amruth

Sponsors

Sri Sharada Ayurveda Pharmacy and RD Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Subjects age group 18 - 70 years both gender 2.Patients diagnosed with COVID-19 positive mild symptomatic patients (Confirmed by RTPCR) 3.Patients with uncomplicated upper respiratory infection a. Spo2 >94% in room air b. Respiratory rate c. No evidence of hypoxaemia or breathlessness 4.Subjects willing to give a written informed consent and come for a regular follow up 5.Subject willing to abide by and comply with the study protocol

Exclusion criteria

Exclusion criteria: 1.Subjects below 18 and above 70 years of age 2.Presence of acute hypoxic respiratory failure. 3.Requiring Intensive care unit (ICU) stay. 4.Patients who need mechanical ventilation. 5.Category 6 or 5 based on modified 7-category ordinal scale of clinical status

Design outcomes

Primary

MeasureTime frame
1 Improvement in Clinical symptoms on 5 point ordinal scale from baseline to end study i.e. 14 days â?¢ Change in LDH, TLC, CRP and D-DIMER from baseline to end of the study i.e. 14 days. Timepoint: Day 0 and Day 14

Secondary

MeasureTime frame
Monitoring for Adverse eventsTimepoint: Day 0 to Day 14

Countries

India

Contacts

Public ContactT N Gurupradad

Sri Sharada Ayurveda Pharmacy and R&D center

rptlprasad@gmail.com7847840073

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026